The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Phantom I think we all know that revenue is for vanity and profit is for sanity and also that EXAS are not making profit BUT the
Americans don't seem to care about profit so I think it is fair to compare on a revenue basis. Normally I would work PE's on profit also but in this case you have to have a different approach.
can't see the reason for a large pharma to buy AGL, as A.N. said in the interview they outsource their drug trial analysis anyway.
If anyone it will be a large player already in the Liquid biopsy space. and that could spark a biding war.
I thought his comment about current lab capacity interesting, 25,000 tests per year at each lab. so 50,000 tests and a price of between $1000 and $2000 per test. So at that we have a lab sales revenue capacity of between $50-$100m per year.
That's now not pie in the sky stuff. I think 99p a tad low.
I think some people haven't fully understood what AGL can and can't do without FDA approval. Simply, in their labs now they can do what they want for research purposes e.g drug trials etc. When accredited ( in a few months) they can process clinical samples, so from real patients etc. That's because the whole lab is accredited.
When selling the device and cassettes into the clinical market e.g. hospitals for third party use, they need FDA for the device and the proposed application use.
I think we all know that after many tears of work, hoops to jump through etc. The the B.O.D would not recommend a £4 offer, nor £8 in fact. So we need patience here, just a bit more than we have already shown. FDA approval will make this the gold standard and with that a substantial de risking and subsequent sp. upgrade. We should not confuse a rerated sp. post clinical lab contracts and FDA approval with a T.O. price. Different all together.
Hi Researcher,
I have in the past spoken to A.N about the derisory broker target of 150p. He responded by saying that the 150p target was for now not after FDA! Also my logic for the April figure is driven by the fact that during the past two years the sp. has gone up by over 30% in April. This I believe is new ISA money inflows and this year people have every reason if not more to pile in ASAP.
Regarding strategy LTB&H has served Mr. Buffet well over the years. Buying into a growing company that pays a growing dividend that is reinvested to gain more dividend will beat a trader over the long term. When warren challenged an actively managed hedge fund not that long ago he won the bet and made even more dosh. Charts in hindesight always show good entry and exit points but not easy in real time.
Be careful when comparing Parsortix with Cellsearch. When granted Parsortix will be the only device ever cleared by FDA to "Harvest" CTC's for subequent analysis. Cellcearch cannot harvest viable cells. That's a major difference and to be the only device in the world approved to harvest rare CTC's will be worth quite a bit.